CME Sponsor:
Imedex

Location:
New York Marriot Downtown
New York, NY

Course Instructors:
Wallace Akerley, MD
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

Chandra P. Belani, MD
Penn State Hershey Cancer Institute
Hershey, Pennsylvania

Jeffrey D. Bradley, MD
Washington University School of Medicine
St. Louis, Missouri

Jessica S. Donington, MD, MSCR
New York University School of Medicine
New York, New York

David S. Ettinger, MD, FACP, FCCP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Tracey L. Evans, MD
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Barbara Gitlitz, MD
University of Southern California
Keck School of Medicine
Los Angeles, California

Ramaswamy Govindan, MD
Washington University School of Medicine
St. Louis, Missouri

Nasser H. Hanna, MD
Indiana University
Indianapolis, Indiana

Daniel D. Karp, MD
University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Corey J. Langer, MD, FACP
University of Pennsylvania
Philadelphia, Pennsylvania

Rogerio C. Lilenbaum, MD
Cleveland Clinic Florida
Weston, Florida

R. Nevin Murray, MD, FRCPC
British Columbia Cancer Agency
Vancouver, BC, Canada

Suresh S. Ramalingam, MD
Winship Cancer Institute
Emory University
Atlanta, Georgia

Charles M. Rudin, MD, PhD
The Sidney Kimmel Comprehensive Cancer Center
John Hopkins University
Baltimore, Maryland

Howard Safran, MD
Brown University Oncology Group
Providance, Rhode Island

Beth Eaby Sandy, CRNP
University of Pennsylvania
Philadelphia, Pennsylvania

Mitchell Schnall, MD, PhD
University of Pennsylvania
Philadelphia, Pennsylvania

Lecia V. Sequist, MD, MPH
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Gerard A. Silvestri, MD, MS
Medical University of South Carolina
Charleston, South Carolina

Anne S. Tsao, MD
University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Maria Werner-Wasik, MD
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania

Number of Credits:
12.0 of AMA PRA Category 1 CreditsTM

Registration:
Early (payment received by 9/22/11) $250.00
Discounted (payment received by 11/10/11) $350.00
Regular (payment received after 11/10/11) $450.00
Group discount (physicians only; cannot be combined with other discounts) -$50.00
Nurses/Residents/Students (proof of eligibility must accompany registration; cannot be combined with other discounts) $99.00

 Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified. To pre-register, registration and payment must be received no later than November 10, 2011. Please register onsite after this date.

For easy registration and any questions, feel free to call toll free at 1-855-2276-6855.

Link

Brochure

Detailed Description:
This educational activity is specifically designed for medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, nurses and other physicians, clinicians, and health care professionals involved and/or interested in the therapeutic management of patients with lung cancer and other thoracic malignancies.

Perspectives in Thoracic Oncology has become the premier source for updates in thoracic oncology; we readily recognize the burgeoning need among thoracic oncology clinicians and researchers for the latest information on the complex biology and treatment of lung cancer. This conference provides a forum to update your knowledge in the field, confirm your current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options. Additionally, in this educational setting, you will have valuable opportunities to interact with your colleagues and learn from renowned faculty, key thought leaders in thoracic oncology, as well as network with the diverse mix of oncologists, surgeons, and pulmonologists who attend.

Learning Objectives:
After successful completion of this course, participants should be able to:
•    Have increased awareness/knowledge regarding:
     o    Advances in lung cancer prevention, including novel chemopreventive strategies and new understanding of the role of smoking
     o    Ongoing trials and novel approaches to adjuvant therapy for lung cancer
•    Have increased confidence in their ability to:
     o    Use surgical and nonsurgical techniques to accurately stage lung cancer
     o    Manage resectable, high-risk, or inoperable lung cancer with single or combined modalities
     o    Diagnose and manage rare thoracic cancers, such as esophageal cancer, mesothelioma, small-cell lung cancer, and thymoma
     o    Manage advanced NSCLC in the frontline, maintenance, and salvage settings
     o    Provide supportive care for patients with lung cancer, including management of therapyrelated side effects and treatment of bone metastases
•    Increase the frequency (compared with current) with which they plan to:
     o    Use mutation status and other biomarkers to predict outcomes and select optimal treatments for each patient
     o    Enroll patients in clinical trials of novel agents or new indications for existing agents